India Approves QDENGA as First Dengue Vaccine

Key Facts

• Approval Date: 20 July 2026 by the Drug Controller General of India (DCGI)
• Vaccine Name: QDENGA (TAK-003)
• Developer: Takeda Biopharmaceuticals, Japan
• Indian Manufacturer: Biological E (partnership started in 2024)
• Target Age Group: 4 to 60 years
• Dengue Virus Serotypes Covered: Four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), making it a tetravalent vaccine
• Annual Production Capacity Planned in India: 50 million doses
• Global Status: Approved in 43 countries since its 2022 launch; over 32 million doses distributed worldwide
• India Dengue Cases Reported in 2025: More than 113,000 cases, accounting for nearly one-third of the global dengue burden
• Nature of Vaccine: Live-attenuated tetravalent vaccine; safe for individuals regardless of prior dengue exposure, eliminating the need for pre-vaccination screening
• Dengue Transmission Vector: Primarily transmitted by Aedes aegypti mosquitoes, which also spread chikungunya and Zika viruses
• Long-term Data: Seven-year follow-up has shown sustained protection against dengue infection and hospitalization for all four serotypes

Background & Context

Dengue fever is a viral disease caused by four related but distinct serotypes of dengue virus (DENV-1 to DENV-4) transmitted mainly by Aedes aegypti mosquitoes. India faces a severe dengue burden with a marked increase over the last two decades, experiencing more than an 11-fold rise in reported cases. This growing public health concern underscores the need for a safe and effective dengue vaccine.

QDENGA, developed by Takeda Biopharmaceuticals in Japan, is a live-attenuated tetravalent vaccine that provides immunity against all four dengue virus serotypes. Importantly, unlike some prior dengue vaccines, QDENGA can be administered without prior screening for previous dengue exposure, simplifying mass immunization efforts.

Takeda partnered with India's Biological E in 2024 to manufacture the vaccine domestically, targeting an annual production capacity of 50 million doses to meet national demand. Since its launch in 2022, QDENGA has been approved in multiple countries, reflecting its global acceptance.

Why This Matters for Exams / Exam Relevance

India’s approval of QDENGA marks the first official authorization of a dengue vaccine in the country, representing a landmark advancement in tackling a major vector-borne disease. Exam questions increasingly focus on recent developments in public health, vaccine technology, and India’s health challenges. Understanding the vaccine’s characteristics—its developer, local manufacturer, target age group, coverage of all dengue serotypes, production capacity, and the epidemiological context of dengue in India—is crucial.

Knowledge of dengue transmission vectors, the distinction of dengue virus serotypes, and the uniqueness of live-attenuated vaccines in immunisation programs are also frequent concepts tested in competitive exams.

Points to Remember

• Dengue is caused by four virus serotypes transmitted mainly by Aedes aegypti mosquitoes.
• QDENGA is India’s first approved dengue vaccine, authorized on 20 July 2026 for individuals aged 4 to 60 years.
• It is a live-attenuated tetravalent vaccine developed by Takeda Biopharmaceuticals (Japan).
• Manufacturing in India is done by Biological E under a partnership established in 2024, with planned capacity of 50 million doses annually.
• More than 113,000 dengue cases were reported in India in 2025, amounting to roughly one-third of the global burden.
• QDENGA does not require prior dengue infection screening before administration.
• Long-term data up to seven years shows continued protection against infection and hospitalisation from all four dengue serotypes.
• India has seen an over 11-fold rise in dengue cases over the past two decades, highlighting the vaccine’s public health importance.